The first BIOTECH SUMMIT AUSTRIA – a milestone event for the Austrian and international biotechnology community – concluded on Friday in Graz, after two days of insightful discussions and networking.
The event, co-hosted by BIOTECH AUSTRIA, the pioneering association for biotechnology in Austria, and the dynamic styrian cluster organization Human.technology Styria, left a lasting impression on the industry, the organizers said in a press release.
The program covered the biotech vision of Big Pharma, funding and financing opportunities for startups and established companies, and a comprehensive examination of the regulatory landscape for clinical trials as well as the impact of AI. Participants included international venture capitalists like Wellington Partners, Hadean Ventures and Gateway Ventures and pharmaceutical companies such as Novartis, Lundbeck, Abbvie and MSD, the organizers said in a press release.
The decision to hold the summit in Graz was based on the remarkable expertise and prominent figures in the research and business landscape in Styria, which hosts a dynamic biotech community, the organizers said in a press release.
The summit exceeded expectations with more than 200 participants from ten countries, an array of enriching activities, including career sessions, startup pitches and extensive networking opportunities. The conference concluded on a high note with a gala dinner and celebration at a stunning event location embedded in a mountain situated below the castle in the heart of Graz, the organizers said in a press release.